BCL-2 Family vs Neurodegenerative Diseases: Complete Comparison

The BCL-2 family of proteins plays a crucial role in regulating apoptosis, or programmed cell death, which is implicated in various neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Recent studies have shown that modulating the activity of BCL-2 proteins can have a significant impact on the progression of these diseases. For example, the use of [[mTOR-inhibitors|mTOR inhibitors]] has been shown to reduce neurodegeneration in models of [[alzheimers-disease|Alzheimer's disease]] and [[parkinsons-disease|Parkinson's disease]]. In contrast, the [[bcl-2-family|BCL-2 family]] of proteins has been shown to have both pro-survival and pro-apoptotic functions, making them a complex target for therapeutic intervention. This comparison will explore the key differences between the BCL-2 family and neurodegenerative diseases, including their mechanisms of action, therapeutic targets, and potential treatments. With a deeper understanding of the relationship between the BCL-2 family and neurodegenerative diseases, researchers can develop more effective treatments for these devastating conditions, such as those using [[rapamycin|rapamycin]] and its analogs.